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A B S T R A C T
Background: A new era for the treatment of chronic 
hepatitis C is about to transpire. With the introduction 
of the first-generation protease inhibitors the efficacy of 
hepatitis C treatment improved significantly. Since then, 
the therapeutic agenda has moved further forward with 
the recent approval of sofosbuvir and the expected approval 
of agents such as simeprevir and daclatasvir. This paper, 
developed parallel to the approval of sofosbuvir, is to serve 
as a guidance for the therapeutic management of chronic 
hepatitis C. 
Methods: We performed a formal search through PubMed, 
Web of Science and ClinicalTrials.gov to identify all clinical 
trials that have been conducted with EMA-approved 
new agents in hepatitis C; for this version (April 2014) 
we focused on sofosbuvir. For each disease category, the 
evidence was reviewed and recommendations are based 
on GRADE. 
Results: We identified 11 clinical trials with sofosbuvir 
and for each disease category recommendations for 
treatment are made. Not all disease categories were studied 
extensively and therefore in some cases we were unable to 
provide recommendations. 
Conclusion: The recent approval of sofosbuvir will most 
likely change the therapeutic landscape of chronic hepatitis 
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C. The use of sofosbuvir-containing regimens can shorten 
the duration of therapy, increase efficacy and result in less 
side effects, compared with standard of care. The efficacy 
relative to standard of care needs to be weighed against 
the increased costs of sofosbuvir. With future approval of 
the other direct-acting antivirals, the outcome of hepatitis 
C treatment will likely improve further and this guidance 
will be updated.
K E Y W O R D S
Direct-acting antivirals, guidance, hepatitis C, sofosbuvir
I N T R O D U C T I O N
The recent approval of sofosbuvir (NS5B polymerase 
inhibitor) and the expected approval of other direct-acting 
antivirals (DAAs) such as simeprevir (protease 
inhibitor) and daclatasvir (NS5A inhibitor) will change 
the therapeutic arena for chronic hepatitis C.1 Until 
2012 the treatment of chronic hepatitis C consisted of 
pegylated interferon with ribavirin (PR) for 24 to 48 
weeks.2 As of April 2012 two first-generation protease 
inhibitors, telaprevir and boceprevir, were approved for 
reimbursement in the Netherlands for patients infected 
with hepatitis C virus (HCV) genotype 1.3 These agents 
improved efficacy3 but their safety profile was poor, 
especially in cirrhotic patients.4-6
In the Netherlands, the estimated hepatitis C 
seroprevalence is 0.1-0.4%, and the highest prevalence 
is seen in first-generation migrants from HCV-endemic 
countries.7-9 Approximately 50% of Dutch patients are 
infected with genotype 1, 30% with genotype 3, 10% with 
genotype 2 and 10% with genotype 4.10
Sofosbuvir can be regarded as a game changer;1 it is an 
orally administered nucleotide polymerase inhibitor, has 
pangenotypic activity in vivo, a high barrier to resistance 
and an acceptable safety profile.11 Approval of other 
drugs in different classes of DAAs may be expected, 
first of all simeprevir (during revision approved) and 
daclatasvir. Additional drugs belonging to the protease 
inhibitor class (asunaprevir, ABT -450/r), the NS5A class 
(ledipasvir, ombitasvir) and the non-nucleoside polymerase 
inhibitor class (dasabuvir) are in later stages of clinical 
development.1
This paper may serve as a current guidance for the 
therapeutic management of chronic hepatitis C. This 
update of the earlier guidance3 is necessary given the 
wealth of new information that has become available since. 
As a static version will become outdated, we encourage 
to review the most current version on the websites of the 
Netherlands Association of Hepato-gastroenterologists 
(NVMDL) or the Netherlands Association of Internal 
Medicine (NIV).12
M E T H O D S
We performed a formal search through the databases 
PubMed, Web of Science and ClinicalTrials.gov to identify 
all relevant clinical trials performed with sofosbuvir, 
peginterferon and/or ribavirin for this version (April 
2014). In addition we searched for future therapies and for 
the product characteristics provided by the US Food and 
Drug Administration (FDA) and the European Medicines 
Agency (EMA). Opinions, letters, narrative reviews, 
pre-clinical studies and articles in another language 
than English, Dutch or German were excluded. The 
search string is attached in supplementary file 1. We 
limited the search for patients with HCV mono-infection. 
For each disease category (treatment-naive, treatment-
experienced and cirrhotic patients) the evidence was 
reviewed by the first and second author. The treatment-
experienced category consists of patients with a prior 
relapse, prior partial response or prior null response. 
Sustained virological response (SVR) is defined as an 
HCV RNA below the lower limit of quantification at 12 
weeks after the end of treatment. We listed the results 
of all individual trials in tables according to disease 
category. The level of evidence was formulated based on 
the GRADE method with the quality of evidence and a 
strength of recommendation (supplementary file 2).13 The 
recommendations in this paper went through a formal 
approval process and were vetted by individual experts and 
all members of the NVMDL and representatives of the NIV. 
R E S U L T S 
We formulated recommendations on the basis of the 
available evidence and information from the label of 
sofosbuvir. The recommendations are given for each 
disease category. When no recommendation is given, 
treatment can be deferred or we refer to the earlier 
guideline.3 First, all currently approved agents and 
expected agents are listed, followed by recommended 
treatment options for the different HCV genotypes once 
sofosbuvir is approved. Recommendations are valid for all 
patients with an indication for treatment as stipulated by 
the earlier guideline.3
List of currently approved drugs for treatment of chronic 
HCV infection:
• Peginterferon: polyethylene glycol attached to 
interferon-a
- Peginterferon a -2a: 180 mg/week
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- Peginterferon a -2b: 1.5 mg/kg/week
• Ribavirin: nucleoside analogue, weight-based dose (< 75 
kg 1000 mg/day and ≥ 75 kg 1200 mg/day, divided over 
two doses)
• Protease inhibitors (-previr):
- Simeprevir (during revision approved, will be 
included in updated version)
- Telaprevir: 2250 mg/day, divided over two or three 
doses
- Boceprevir: 2400 mg/day, divided over three doses
• Nucleotide polymerase inhibitor (-buvir):
- Sofosbuvir: 400 mg/day, in one dose
 No data in patients with renal impairment are 
available (eGFR < 30 ml/min/m2)
List of HCV drugs in development:
This list is not exhaustive and can be expanded; we aimed 
to include drugs that are in phase III development.1










• Non-nucleoside polymerase inhibitors (-buvir):
- Dasabuvir (ABT-333)
Watchful waiting
Watchful waiting is a preferred strategy in patients who do 
not have an urgent indication for treatment based on the 
earlier guideline,3 in patients where no recommendation 
is given or when the quality of evidence is low and the 
strength of recommendation is weak (Level: C2). There 
are several arguments in favour of this strategy: (A) not all 
patient groups are represented in clinical trials, therefore 
the evidence for recommendations is weak in certain 
disease categories, (B) with the introduction of sofosbuvir 
we still need pegylated interferon and ribavirin in many 
patients and (C) improved efficacy and reduced toxicity is 
expected from interferon-free combinations of DAAs likely 
to be approved in the near future.1
Recommendations by HCV genotype, disease stage and 
treatment history
Genotype 1 treatment-naive patients 
Recommendation: Sofosbuvir, peginterferon and 
weight-based ribavirin for 12 weeks (Level: B1)
Several trials have been performed in genotype 1 
treatment-naive patients (figure 1). The recommended therapy 
was studied in two trials: NEUTRINO and ATOMIC. The 
NEUTRINO trial was a single-group open-label trial that 
achieved 89% SVR.14 Patients without cirrhosis obtained 
90% SVR in the ATOMIC trial. There was no additional 
benefit (i.e. no difference in SVR) for extension of treatment 
to 24 weeks or by extension with sofosbuvir monotherapy or 
sofosbuvir and ribavirin (n = 264).15 The dose of sofosbuvir 
was determined on the basis of the PROTON study where 
200 and 400 mg of sofosbuvir were compared. Here, the 
SVR rate was irrespective of the dose of sofosbuvir; however, 
three patients in the 200 mg group had a viral breakthrough, 
hence the selection of 400 mg.16 Only one trial was of high 
quality,16 the other trials were open-label trials of a low to 
moderate quality.13
Genotype 1 treatment-experienced patients 
Recommendation: No recommendation based on data 
The ELECTRON trial was the only trial that included 
treatment-experienced genotype 1 patients; these patients 
received sofosbuvir with ribavirin (12 weeks), only one 
of ten patients achieved SVR.17 The label recommends 
consideration of treatment with sofosbuvir, peginterferon 
and ribavirin for 12 weeks or extension to 24 weeks,18 but 
in our opinion more data are needed. 
Genotype 1 cirrhotic patients 
Recommendation: Watchful waiting (Level: C1)
Two clinical trials included patients with cirrhosis; the 
NEUTRINO trial reached 80% SVR with sofosbuvir on top 
of PR14 and three of six cirrhotic patients with unfavourable 
characteristics achieved SVR with sofosbuvir and ribavirin 
in a single-centre trial.19 The quality of evidence for 
sofosbuvir is low, the toxicity of the previous standard of 
care in cirrhotic patients is high4 and future agents (e.g. 
simeprevir) are promising, hence watchful waiting is 
recommended.
Future perspective
For genotype 1 patients, multiple trials are currently 
underway; promising agents are simeprevir, 
asunaprevir, ABT-450/r (protease inhibitors), daclatasvir, 
ledipasvir, ombitasvir (NS5A inhibitors) and dasabuvir 
(non-nucleoside polymerase inhibitor). All oral treatment 
is expected to become possible in the near future for both 
treatment-naive and treatment-experienced patients.
Simeprevir and sofosbuvir with or without ribavirin were 
studied in the COSMOS trial in two cohorts, in prior null 
responders with F0-2 fibrosis (cohort 1) and in treatment 
naive or prior null responders with F3-4 fibrosis (cohort 
2). High SVR rates were seen in cohort 1 (91-100%)20 and 
cohort 2 (94-96%).21,22 Therefore the combined treatment 
of simeprevir and sofosbuvir can be a reasonable option for 
these categories of patients in the near future. Simeprevir 
with PR has been studied in the ASPIRE, PILLAR and 
PROMISE studies and high SVR rates of 70-85% are seen 
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in cirrhotic patients with prior relapse or prior partial 
response.23-25 Clinical trials with simeprevir have shown 
that a Q80K mutation in genotype 1a patients significantly 
reduces the efficacy of the treatment.26
Sofosbuvir plus daclatasvir with or without ribavirin for 
12 or 24 weeks was studied in the AI444040 study, 126 
treatment-naive genotype 1 patients achieved 98% SVR. 
Furthermore 41 patients who failed therapy with telaprevir 
or boceprevir had 98% SVR with 24 weeks of sofosbuvir 
and daclatasvir with or without ribavirin. Cirrhotic patients 
were excluded.27 Currently a compassionate use program 
of sofosbuvir and daclatasvir with or without ribavirin for 
Child-Pugh C patients is available.
The combination of an NS5B polymerase inhibitor and an 
NS5A inhibitor is also being studied in the LONESTAR, 
ION-1, ION-2 and ION-3 studies. The LONESTAR is a 
single-centre open-label study in genotype 1 treatment-naive 
patients and patients with virological failure on protease 
inhibitors. An SVR of 95-100% (n = 100) with different 
regimens (i.e. sofosbuvir/ledipasvir with or without 
ribavirin, 8 or 12 weeks) was reached.28 In the ION-1 
and ION-2 trials, SVR was reached in 94-98% of the 
patients with 12 weeks of sofosbuvir/ledipasvir with or 
without ribavirin.29,30 In the ION-3 trial treatment-naive 
non-cirrhotic patients achieved 94% SVR with 8 weeks of 
sofosbuvir/ledipasvir.31 Phase 2a trials have been performed 
with daclatasvir and asunaprevir in combination with PR 
or the non-nucleoside polymerase inhibitor BMS-791325 in 
prior null responders and treatment-naive patients for 12-24 
weeks. High SVR rates, 92-100%, were achieved.32-34 Three 
Figure 1. Trials in HCV genotype 1 patients
Trial Regime (weeks) n SVR SVR (95% CI) QoE
0 4 8 12 24 // 48 0  5 0  1 0 0
Genotype 1, treatment naive
PROTON SOF(200)+PR PR PR  
48 90% A
SOF(400)+PR PR PR 47 91% A
placebo + PR PR 26 58% A
NEUTRINO SOF+PR 292 89% C
ELECTRON SOF(+RBV) 25 84% C
ATOMIC SOF+PR 52 90% B
SOF+PR 109 93% B
SOF+PR SOF(+RBV) 155 91% B
Osinusi et al.∫ SOF+RBV(wb) 10 90% C
SOF+RBV(wb) 25 68% C
SOF+RBV(600) 25 48% C
Genotype 1, treatment experienced
ELECTRON SOF+RBV 10 10% C
Genotype 1, cirrhosis
NEUTRINO SOF+PR 54 
† 80% C




PR = pegylated interferon with ribavirin; QoE = Quality of Evidence (A: high, B: moderate, C: low); RBV = ribavirin; SOF = sofosbuvir; 
SVR = sustained virological response; wb: weight-based; *calculated 95% CI, ∫first cohort early-moderate fibrosis; second and third cohort 
unfavourable characteristics. In cirrhotics: †treatment naive.
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studies (n = 571, n = 297 and n = 473) evaluated multiple 
regimens with ABT-450/r, dasabuvir and ombitasvir with or 
without ribavirin in different combinations and durations. 
High SVR rates (83-97%) were seen in treatment-naive 
and treatment-experienced non-cirrhotic patients.35-37 The 
TURQUOISE-II trial studied the same regimen (with 
ribavirin) in compensated cirrhotic patients for 12 (n = 208) 
and 24 (n = 172) weeks. SVR was achieved in 92% and 96% 
of the patients, respectively.38
Genotype 2 treatment-naive patients
Recommendation: Sofosbuvir and weight-based ribavirin 
for 12 weeks (Level: A1)
Patients with an HCV genotype 2 infection have an SVR 
rate of 74-83% with PR for 24 weeks.3,39,40 Multiple trials 
with sofosbuvir have been performed in treatment-naive 
genotype 2 patients (figure 2). Two trials of high quality 
and one of low quality studied the recommended 
interferon-free regimen (POSITRON, FISSION and 
VALENCE) with consistent good results. The POSITRON 
trial included patients for whom interferon was not an 
option and reached 93% SVR irrespective of cirrhosis.11 
In the FISSION trial SVR was reached in 97% of patients, 
while in patients treated with peginterferon and ribavirin 
(800 mg) for 24 weeks SVR was achieved in 78%.14 The 
results of the VALENCE trial are similar to FISSION and 
POSITRON for the recommended regimen.41,42 Addition 
of peginterferon showed no improved SVR rates.16,17 In 
conclusion, sofosbuvir with ribavirin for 12 weeks in 
genotype 2 patients was effective in high-quality trials 
with implications for clinical practice because of an 
interferon-free regimen with a shorter treatment duration 
than the previous standard of care.3 
Genotype 2 treatment-experienced patients 
Recommendation: Sofosbuvir and weight-based ribavirin 
for 12 weeks (Level: B1)
In the FUSION trial, genotype 2 patients were treated with 
either 12 or 16 weeks of sofosbuvir and ribavirin. Patients 
in the 12-week arm received four weeks of placebo, they 
reached 86% SVR and in the 16-week arm this was 94%. 
For non-cirrhotic patients the FUSION trial failed to 
demonstrate additional value of extending the treatment 
to 16 weeks, hence the recommendation of 12 weeks.11 
The POSITRON included 17 patients with unacceptable 
side effects in prior treatment and they achieved an SVR 
of 78% with sofosbuvir and ribavirin.11 The results of 
the VALENCE trial demonstrated a 90% SVR with the 
recommended regimen.18,42 In another trial there was no 
additional value of peginterferon.43 Again this treatment 
has significant implications for clinical practice because 
of the high SVR rates without interferon and shorter 
treatment duration. The trials were of high11 and low 
quality41,43 with consistent results.
Genotype 2 cirrhotic patients 
Recommendation: Sofosbuvir and weight-based ribavirin 
for 12 weeks (Level: B1)
There are four trials that evaluated sofosbuvir and ribavirin 
for 12 weeks in cirrhotic genotype 2 patients, mainly 
treatment-naive patients were studied. The FISSION 
demonstrated an SVR of 83% (n = 12), treatment with 
peginterferon and ribavirin (800 mg) for 24 weeks led to 
62% SVR (n = 13).14,18 The POSITRON trial showed an SVR 
of 94%. In treatment-experienced patients with cirrhosis 
an extension of duration of treatment from 12 to 16 weeks 
led to an improvement in SVR from 60% (n = 10) to 78% 
(n = 9) in the FUSION trial.11 The VALENCE trial shows 
82% SVR in 11 cirrhotic patients with sofosbuvir and 
ribavirin (12 weeks).18,44 All trials included only a small 
number of patients, but implications for clinical practice 
are high as treatment is warranted and toxicity is expected 
to be less than with standard of care.
Future perspective
For genotype 2 patients the regimen of sofosbuvir with 
ribavirin leads to high SVR rates. Also, the AI444040 
trial studied 26 treatment-naive genotype 2 patients; 24 
(92%) achieved SVR with different regimens consisting of 
sofosbuvir and daclatasvir with or without ribavirin for 24 
weeks. Cirrhotic patients were excluded.27
Genotype 3 treatment-naive patients 
Recommendation: 
• Watchful waiting
• Peginterferon and ribavirin (800 mg) for 24 weeks
• Sofosbuvir and weight-based ribavirin for 24 weeks
• Sofosbuvir, peginterferon and weight-based ribavirin for 
12 weeks 
(Level A2)
For genotype 3 patients, several options for treatment are 
available and the physician has to decide which strategy 
is currently better for the individual patient. Historically 
genotype 2 and genotype 3 patients achieve an SVR of 
70-80% with peginterferon and ribavirin (800 mg) for 
24 weeks.3 
Different trials have been performed in genotype 3 
patients; all trials with 12 weeks of sofosbuvir and 
ribavirin fail to show superiority in comparison with 
PR treatment (figure 3).14 The addition of peginterferon 
or extension of treatment to 24 weeks showed improved 
results. In the ELECTRON trial, 25 patients received 
12 weeks of sofosbuvir and ribavirin combined with 
peginterferon for 0, 4, 8 or 12 weeks: all patients achieved 
SVR.17 The VALENCE trial obtained 94% SVR in 105 
patients with sofosbuvir with ribavirin for 24 weeks.18,42 
Because of the above-mentioned results peginterferon 
with ribavirin (800 mg) for 24 weeks remains an option 
for therapy, ribavirin should be weight based in patients 
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Figure 2. Trials in HCV genotype 2 patients
Trial Regime (weeks) n SVR SVR (95% CI) QoE
0 4 8 12 24 // 48 0  5 0  1 0 0
Genotype 2, treatment naive
POSITRON SOF+RBV 109 93% A
Placebo 34 0% A
FISSION SOF+RBV 70 97% A
PR (RBV 800) 67 78% A
PROTON SOF+PR 25 
# 92% B






VALENCE SOF+RBV 32 97% C
Genotype 2, treatment experienced
FUSION SOF+RBV 36 86% A
SOF+RBV 32 94% A




VALENCE SOF+RBV 41 90% C
LONESTAR-2* SOF+PR 23 96% C
Genotype 2, cirrhosis




FISSION SOF+RBV 49 
†# 47% A










LONESTAR-2* SOF+PR 14 
‡ 93% C
PR = pegylated interferon with ribavirin; QoE = Quality of Evidence (A: high, B: moderate, C: low); RBV = ribavirin; SOF = sofosbuvir; 
SVR = sustained virological response; *calculated 95% CI, # data of genotype 2 and 3 combined. In cirrhotics: † treatment naive, ‡ treatment 
experienced.
Berden et al. Treatment of chronic hepatitis C virus infection.
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with baseline characteristics associated with a poor 
response.3 Other options are watchful waiting, sofosbuvir 
with ribavirin for 24 weeks or sofosbuvir with PR for 12 
weeks. The choice for one of the regimens is dependent on 
the individual patient, bearing in mind the higher costs 
of sofosbuvir.
Genotype 3 treatment-experienced patients 
Recommendation: Watchful waiting 
Alternative strategy: Sofosbuvir and weight-based 
ribavirin for 24 weeks OR sofosbuvir, peginterferon and 
weight-based ribavirin for 12 weeks (Level: B2)
Results of sofosbuvir for treatment-experienced genotype 
3 patients are disappointing with high imprecision; only 
the VALENCE and LONESTAR-2 trials show acceptable 
results but are of low quality. The FUSION trial showed 
that extension of treatment by 4 weeks led to improvement 
of SVR.11 Extension to 24 weeks was done in the VALENCE 
study and an SVR of 79% was achieved, while for the 
non-cirrhotic patients the SVR rate was 87%.18,42 The 
LONESTAR-2 trial showed an SVR of 83% in 24 patients 
treated with sofosbuvir and PR for 12 weeks.43 In the 
near future more effective combinations of DAAs are 
expected. Therefore, the general recommendation is 
watchful waiting. As an alternative strategy sofosbuvir with 
ribavirin for 24 weeks or sofosbuvir with PR for 12 weeks 
may be considered.
Genotype 3 cirrhotic patients 
Recommendation: Watchful waiting
Alternative strategy: Sofosbuvir and weight-based 
ribavirin for 16 weeks OR sofosbuvir and weight-based 
ribavirin for 24 weeks (Level: B2)
Genotype 3 cirrhotic patients were treated with sofosbuvir 
in five trials with moderate SVR rates.
The FUSION trial showed an SVR of 19% with 12 weeks of 
sofosbuvir and ribavirin in treatment-experienced cirrhotic 
patients; extension of treatment to 16 weeks showed an 
SVR of 61%. The VALENCE trial studied 24 weeks of 
sofosbuvir and ribavirin in 60 cirrhotic patients, with 92% 
SVR in treatment-naive patients and 62% in treatment-
experienced patients.18
Based on the above results with small numbers of patients, 
we advise watchful waiting as the recommended strategy 
since SVR rates are rather low, mainly in treatment-
experienced patients and sofosbuvir is expensive. 
Alternative regimens are sofosbuvir and ribavirin for 16 
weeks or 24 weeks. 
Future perspective
Daclatasvir is one of the agents that are expected to be 
approved in the near future. The COMMAND GT 2/3 study 
included 151 genotype 2 and 3 patients and these patients 
received either 12 or 16 weeks of daclatasvir with PR or 24 
weeks placebo with PR. SVR rates were 69% (12 weeks), 
67% (16 weeks) and 59% (placebo). Treatment failure was 
mainly due to relapse in cirrhotic patients in the 12-week 
group.45 The combination of sofosbuvir and daclatasvir 
with or without ribavirin for 24 weeks does hold promise 
for treatment-naive genotype 3 patients as SVR rates of 
89% can be reached.27 Treatment-naive genotype 3 patients 
received sofosbuvir/ledipasvir with or without ribavirin in 
the ELECTRON-2 trial (12 weeks). Dual therapy reached 
64% SVR (n=25) while triple therapy reached 100% SVR 
(n=26).46
Genotype 4 treatment-naive patients
Recommendation: Sofosbuvir, peginterferon and 
weight-based ribavirin for 12 weeks. (Level: C1) 
The recommended regimen is being studied in the 
NEUTRINO trial, 28 patients were treated with sofosbuvir 
and PR for 12 weeks and reached 96% SVR.14 Extension 
of therapy to 24 weeks did not show an improved effect.15 
Egyptian patients (n = 28) received an interferon-free 
regimen for 12 or 24 weeks and achieved 79% and 100% 
SVR, respectively.47 In general, data are scarce (figure 4) but 
in view of the high SVR rates sofosbuvir-based treatment 
is recommended.
Genotype 4 treatment-experienced patients
Recommendation: No recommendation based on data 
There are no published data on sofosbuvir-based treatment 
available for treatment-experienced genotype 4 patients. 
The most recent data of the Egyptian study showed 59% 
SVR (n = 17) with 12 weeks of sofosbuvir and ribavirin 
and 87% SVR (n = 15) with 24 weeks of sofosbuvir and 
ribavirin.47,48 The label recommends sofosbuvir and PR for 
12 weeks, but more data are needed. 
Genotype 4 cirrhotic patients
Recommendation: No recommendation based on data 
Only a limited number of cirrhotic genotype 4 patients 
have been studied. The NEUTRINO trial included two 
cirrhotic genotype 4 patients of whom one achieved SVR 
with sofosbuvir and PR for 12 weeks.14 In the Egyptian 
study treatment-naive cirrhotic patients achieved 33% 
(n = 3) and 100% (n = 3) SVR with 12 and 24 weeks of 
sofosbuvir and ribavirin. The SVR rates in treatment-
experienced patients were 50% and 100% in both groups 
(n = 8).47 
Future perspective
Simeprevir with PR (24 or 48 weeks) is studied in genotype 
4 patients, overall 65% of the patients reached SVR with 
higher SVR rates in treatment-naive and relapse patients 
(83% and 86%).49 Asunaprevir with PR has been studied 
in 18 genotype 4 patients for 24 weeks and 89% reached 
SVR, the control group consisted of seven patients of whom 
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Figure 3. Trials in HCV genotype 3 patients
Trial Regime (weeks) n SVR SVR (95% CI) QoE
0 4 8 12 24 // 48 0  5 0  1 0 0
Genotype 3, treatment naive
POSITRON SOF+RBV 98 61% A
Placebo 37 0% A
FISSION SOF+RBV 183 56% A
PR (RBV 800) 176 63% A
PROTON SOF+PR 25 
# 92% B






VALENCE SOF+RBV 11 27% C
SOF+RBV 105 94% C
Genotype 3, treatment experienced
FUSION SOF+RBV 64 30% A
SOF+RBV 63 62% A




VALENCE SOF+RBV 145 79% C
LONESTAR-2* SOF+PR 24 83% C
Genotype 3, cirrhosis




FISSION SOF+RBV 49 
# † 47% A
PR (RBV 800) 50 
# † 38% A








LONESTAR-2* SOF+PR 12 
‡ 83% C
PR = pegylated interferon with ribavirin; QoE = Quality of Evidence (A: high, B: moderate, C: low); RBV = ribavirin; SOF = sofosbuvir; 
SVR = sustained virological response; *calculated 95% CI, # data of genotype 2 and 3 combined. In cirrhotics: † treatment naive, ‡ treatment 
experienced.
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43% reached SVR with PR for 48 weeks.50 Furthermore 
daclatasvir was studied in 24 treatment-naive genotype 4 
patients, 67% achieved SVR with 20 mg daclatasvir and 
100% achieved SVR with 60 mg daclatasvir with PR for 
24 weeks.51 Daclatasvir with asunaprevir and BMS-791325 
were studied in 12 patients, 11 achieved SVR and 1 
patient is still in follow-up.52 The PEARL-I study included 
86 treatment-naive genotype 4 patients who received 
ABT-450/r plus ombitasvir with or without ribavirin (12 
weeks), 91-100% SVR was achieved.53 Patient numbers are 
limited but in view of the high SVR rates of future therapy, 
watchful waiting can be considered in genotype 4 patients 
until further data allow approval of newer DAAs.
Genotype 5, 6
Data from well-powered clinical comparative trials for 
genotype 5 and 6 patients are lacking. We think it is 
unlikely that such data will become available in the 
near future for the novel DAAs. Therefore we consider 
it acceptable to use treatment results for genotype 1 as a 
template for treatment of genotype 5 and 6. 
Genotype 5, 6 treatment-naive patients
Recommendation: 
• Genotype 5: No recommendation based on data, consider 
genotype 1 treatment regimen as template (Level: C2)
Figure 4. Trials in HCV genotype 4, 5 and 6 patients
Trial Regime (weeks) n SVR SVR (95% CI) QoE
0 4 8 12 24 // 48 0  5 0  1 0 0
Genotype 4, treatment naive
NEUTRINO* SOF+PR 28 96% C
ATOMIC SOF+PR 11 82% C
Ruane et al.* SOF+RBV 14 79% C
SOF+RBV 14 100% C
Genotype 4, treatment experienced
Ruane et al.* SOF+RBV 17 59% C
SOF+RBV 15 87% C
Genotype 4, cirrhosis
NEUTRINO* SOF+PR 2 
† 50% C








Genotype 5 and 6, treatment naive
NEUTRINO* SOF+PR 7 100% C
ATOMIC SOF+PR 5 100% C
Genotype 5 and 6, treatment experienced
No available trials
PR = pegylated interferon with ribavirin; QoE = Quality of Evidence (A: high, B: moderate, C: low); RBV = ribavirin; SOF = sofosbuvir; 
SVR = sustained virological response; *calculated 95% CI, if 100% SVR then no CI could be calculated. In cirrhotics: † treatment naive, ‡ treatment 
experienced.
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• Genotype 6: sofosbuvir, peginterferon and weight-based 
ribavirin for 12 weeks (Level: C2) 
Only 12 treatment-naive patients with genotype 5 or 6 have 
been treated in two trials (NEUTRINO and ATOMIC). 
In the NEUTRINO trial six genotype 6 patients and one 
genotype 5 patient were treated with 12 weeks of sofosbuvir 
and PR and all patients achieved SVR.14 In the ATOMIC 
trial only five patients with genotype 6 received sofosbuvir 
with PR for 24 weeks, all achieved SVR.15 More data 
are needed, however, considering the high SVR rates a 
sofosbuvir-based treatment is recommended for genotype 6. 
Genotype 5,6 treatment-experienced patients
Recommendation: No recommendation based on data, 
consider genotype 1 treatment regimen as template 
(Level: C2)
There are no data on sofosbuvir-based treatment available 
for treatment-experienced genotype 5 or 6 patients. 
Genotype 5, 6 cirrhotic patients
Recommendation: No recommendation based on data, 
consider genotype 1 treatment regimen as template 
(Level: C2)
The NEUTRINO trial included 20% cirrhotic patients but 
it is unknown if cirrhotic genotype 5 or 6 patients were 
included.14 
Drug-drug interactions
Many of the DAAs are substrates of CYP450 and the 
membrane transporter P-gp; they may both be the victim 
of drug interactions or cause these interactions with other 
agents.54,55 Sofosbuvir has a relatively mild drug interaction 
profile as it is only a substrate of P-gp and does not 
interfere with CYP450 enzymes. It is necessary to check 
for interacting co-medications, including over the counter 
drugs (e.g. St. John’s Wort), before starting DAA-based 
HCV treatment (http://www.hep-druginteractions.org).
Summary box of recommendations for HCV monoinfected patients
Genotype Patient group Recommendation Future perspective
1 Treatment naive Sofosbuvir, peginterferon and ribavirin for 12 weeks Daclatasvir, simeprevir, ledipasvir, 
asunaprevir, ABT-450/r, dasabuvir, 
ombitasvirTreatment experienced No recommendation based on data 
Cirrhotic Watchful waiting
2 Treatment naive Sofosbuvir and ribavirin for 12 weeks Daclatasvir
Treatment experienced Sofosbuvir and ribavirin for 12 weeks
Cirrhotic Sofosbuvir and ribavirin for 12 weeks
3 Treatment naive Physician opinion to determine the strategy, options: 
• Watchful waiting
• Peginterferon and ribavirin (800 mg) for 24 weeks
• Sofosbuvir and ribavirin for 24 weeks
• Sofosbuvir, peginterferon and ribavirin for 12 weeks 
Daclatasvir, ledipasvir
Treatment experienced Watchful waiting
Alternative strategy: 
• Sofosbuvir and ribavirin for 24 weeks OR 
• Sofosbuvir, peginterferon and ribavirin for 12 weeks
Cirrhotic Watchful waiting
Alternative strategy: 
• Sofosbuvir and ribavirin for 16 weeks OR 
• Sofosbuvir and ribavirin for 24 weeks
4 Treatment naïve Sofosbuvir, peginterferon and ribavirin for 12 weeks Simeprevir, daclatasvir, 
asunaprevir, ABT-450/r, ombitasvir
Treatment experienced No recommendation based on data
Cirrhotic No recommendation based on data
5, 6 Treatment naive Genotype 5: No recommendation based on data, 
consider genotype 1 treatment regimen as template
Genotype 6: Sofosbuvir, peginterferon and ribavirin 
for 12 weeks
Treatment experienced No recommendation based on data, consider genotype 
1 treatment regimen as template
Cirrhotic No recommendation based on data, consider genotype 
1 treatment regimen as template
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D I S C U S S I O N
The current guidance comes at a time when the landscape 
of HCV treatment is undergoing a rapid change. There 
are currently four comparable guidances, one was issued 
by the American Association for the Study of Liver 
Diseases (AASLD), one by European Association for the 
Study of the Liver (EASL) and the other two are guidances 
from Germany.56-59 Our guidance differs from the AASLD 
and EASL guidances and we do not offer advice on the 
use of simeprevir and daclatasvir in this version. The 
main difference with the other guidances is that we offer 
the clinician the option to defer treatment in genotype 
3 and some subgroups of patients. The reason is that, 
except for the VALENCE trial, the currently published 
evidence has not proved efficacy beyond standard of care. 
The proportion of cirrhotic patients in the various trials 
is disappointingly low and recommendations cannot be 
given for this category, with the exception of genotype 
2. This contrasts with clinical practice where cirrhotic 
patients have the most urgent treatment indication.3 
For genotypes 5 and 6 the current evidence is poor. 
The AASLD, EASL and German guidances recommend 
sofosbuvir triple therapy for genotype 5 and 6. The 
consensus in the Hepatology Committee was that the 
evidence for sofosbuvir was acceptable for genotype 6 
naive patients, while we recommend standard of care or 
considering the genotype 1 regimen as template for other 
disease categories in genotype 5 and 6. At odds with 
other guidances we do not recommend sofosbuvir-based 
treatment for genotype 1 and 4 treatment-experienced 
patients given the lack of evidence. This guidance only 
includes recommendations for HCV monoinfected 
patients. Sofosbuvir and other DAAs are also being 
studied in HIV/HCV patients; this will be updated in a 
new version of this guidance.
The rapid pace of development of drugs to treat HCV 
infection introduces not only great expectations but also 
uncertainty about the optimal timing to initiate therapy.60 
The key question here is which patients can benefit 
from the DAAs that are now available. Sofosbuvir is 
a first-generation polymerase inhibitor that is in the 
vanguard of a wave of drugs that have the potential to 
cure HCV. With the approval of the EMA, sofosbuvir will 
be released on the Dutch market soon. As medication is 
an important costdriver, the added efficacy of sofosbuvir 
relative to standard of care should be weighed carefully.61 
As the pipeline with new antiviral drugs is full and new 
releases can be expected in 2014 and 2015, this paper 
serves as a dynamic document and will be continually 
edited and updated.12
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Supplementary file 1. Search 
An initial search was conducted on 25-Feb-2014 with the term: 
‘2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-
3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphos-
phorylamino) propionic acid isopropyl ester [Supplementary 
Concept]’ as a MeSH term. Furthermore we included ‘sofos-
buvir OR GS-7977 OR PSI 7977 OR PSI7977 OR PSI-7977 
OR Sovaldi’ in our search. In total 98 articles were found in 
PubMed. All were scanned on title and abstract for inclusion. 
New results of the search were added until 8-Apr-14. For the 
future perspectives we searched the agents in phase III of 
clinical trials, including simeprevir (as MeSH combined with 
‘simeprevir OR TMC 435350 OR TMC435350 OR TMC-435350 
OR Olysio OR TMC 435 OR TMC435 OR TMC-435’, with the 
limit of clinical trials). We did the same for daclatasvir, ledi-
pasvir, asunaprevir and the ABT formulations in PubMed. 
Clinicaltrials.gov was used to get more information about the 
unpublished trials. Prior to submission, the abstracts of the 
International Liver Congress 2014 (49th annual meeting of the 
European Association for the Study of the Liver) were scanned 
and relevant studies were included in the future perspectives of 
the different genotypes.
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